| Market Cap | 1.23B | P/E | - | EPS this Y | -35.40% | Ern Qtrly Grth | 1,409.80% |
| Income | 157.08M | Forward P/E | - | EPS next Y | -7.80% | 50D Avg Chg | 9.00% |
| Sales | 231.94M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 35.00% |
| Dividend | N/A | Price/Book | 29.00 | EPS next 5Y | - | 52W High Chg | -3.00% |
| Recommedations | - | Quick Ratio | 5.68 | Shares Outstanding | 129.95M | 52W Low Chg | 171.00% |
| Insider Own | 13.30% | ROA | 85.52% | Shares Float | 108.84M | Beta | 1.99 |
| Inst Own | 17.14% | ROE | 127.30% | Shares Shorted/Prior | -/- | Price | 9.57 |
| Gross Margin | 88.47% | Profit Margin | 67.72% | Avg. Volume | 354 | Target Price | - |
| Oper. Margin | 89.40% | Earnings Date | Jul 29 | Volume | 450 | Change | 0.00% |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.